The antibody-drug conjugate landscape continues to evolve beyond traditional ADC formats, with multi-payload ADCs rapidly emerging as one of the industry’s most closely watched areas of innovation. Designed to address challenges such as tumour heterogeneity, treatment resistance, and limited durability, these next-generation molecules have attracted growing investment despite limited clinical validation to date.
In this exclusive webinar, Beacon will present the key findings from our newly released Multi-Payload ADC Landscape Report, featuring analysis of pipeline growth, target and payload strategies, competitive activity, clinical development trends, and upcoming value-inflection events. Following the report presentation, join a fireside chat with a leading industry expert to discuss what these insights mean for the future of ADC development, partnering, and portfolio strategy.
Key Highlights:
- Exclusive first look at Beacon’s new Multi-Payload ADC Landscape Report and its key findings.
- Analysis of market growth, pipeline activity, and the maturity of the multi-payload ADC landscape.
- Insights into target selection, payload combinations, linker strategies, and emerging design trends.
- Expert discussion on the opportunities, risks, and future outlook for multi-payload ADCs.
Why Watch?
- Gain early access to proprietary market intelligence before key clinical data emerges.
- Understand where the industry is investing and how the competitive landscape is evolving.
- Identify emerging opportunities across targets, payload strategies, and partnership activity.
- Learn which upcoming clinical catalysts could have the greatest impact on the market.
Register now for an informative session.
Webinar Leaders
Brian A. Mendelsohn
Independent Consultant and Antibody Conjugate Expert, MBC Consulting LLC
Raj Kumar
Commercial Director, Beacon
Christophe Homer
Consulting Director, Beacon
You May Also Be Interested In…
Learn More About ADC
- The Most Comprehensive Way to Search the ADC Drug Development Landscape: Unique search ontologies based on ADC drug and trial characteristics
- Market Leading Approach to ADC Preclinical & Clinical Data Curation: Manual curation of key ADC research and development data points by ADC research scientists
- Seamlessly Integrate Commercial & Scientific Data all in One Place: Search ADC company and deal data based on their pipeline and technologies.
- Unrivalled Granularity in Reports & Analysis: Our search ontology and technology indexing enable comprehensive analysis not seen elsewhere.
What is Beacon?
Beacon is the essential intelligence platform for R&D decision-makers working in pharma and biotech, offering unique technology and drug datasets for complex therapeutics and disease areas.
Our market-defining proprietary ontologies, manual data curation, and accurate and comprehensive life science data, provide our customers with unparalleled visibility of the drug, trial and commercial landscape.
This is why 24 of the top 25 pharmaceutical companies trust Beacon to power their critical pipeline, competitive, and commercial decisions.
We’d welcome the opportunity to show you how Beacon can transform your data strategy. Book your personalized demonstration today!
